Lanthanum Carbonate (Fosrenol, BAY77-1931)

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia, Kidney Disease

Trial Timeline

Oct 10, 2013 → Aug 5, 2016

NCT ID

NCT01955876

About Lanthanum Carbonate (Fosrenol, BAY77-1931)

Lanthanum Carbonate (Fosrenol, BAY77-1931) is a pre-clinical stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01955876. Target conditions include Hyperphosphatemia, Kidney Disease.

What happened to similar drugs?

2 of 15 similar drugs in Hyperphosphatemia were approved

Approved (2) Terminated (0) Active (13)

🔄KHK7791 + PlaceboKyowa KirinPhase 3

🔄KHK7791Kyowa KirinPhase 3

🔄SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3

🔄PA21Kissei PharmaceuticalPhase 3

🔄Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01955876	Pre-clinical	Completed	Oct 10, 2013	Aug 5, 2016	Hyperphosphatemia

Competing Products

20 competing products in Hyperphosphatemia

See all competitors

Product	Company	Stage	Hype Score
EOS789 + Placebo + Renvela	Chugai Pharmaceutical	Phase 1	29
DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet	Daiichi Sankyo	Phase 1	29
ASP1585 + Placebo + Sevelamer hydrochloride	Astellas Pharma	Phase 2	35
ASP1585	Astellas Pharma	Phase 2	35
the standard-dose group (4 g/day)	Kyowa Kirin	Pre-clinical	33
KHK7791 + Placebp	Kyowa Kirin	Phase 2	35
KHK7791	Kyowa Kirin	Phase 2	35
KHK7791 + Placebo	Kyowa Kirin	Phase 3	40
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)	Kyowa Kirin	Pre-clinical	33
KHK7791 + Placebo	Kyowa Kirin	Phase 3	40
KHK7791	Kyowa Kirin	Phase 3	40
KHK7791 + Placebo	Kyowa Kirin	Phase 2	35
KHK7791	Kyowa Kirin	Phase 3	40
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl	Novartis	Phase 2	35
SBR759A + SBR759A + SBR759A + SBR759A + SBR759A	Novartis	Phase 3	40
PA21	Kissei Pharmaceutical	Phase 3	40
Placebo + Sevelamer Carbonate (GZ419831)	Sanofi	Phase 3	40
Placebo + Sevelamer carbonate	Sanofi	Phase 2	35
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet	Bayer	Pre-clinical	23
Lanthanum Carbonate (BAY77-1931)	Bayer	Phase 2	32